Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
View Top Employees from Medigene AGWebsite | http://www.medigene.com |
Revenue | $8 million |
Funding | $117.7 million |
Employees | 108 (83 on RocketReach) |
Founded | 1994 |
Address | 11 Lochhamer St, Planegg, Bavaria 82152, DE |
Phone | +49 89 2000330 |
Fax | +49 89 2000332920 |
Industry | Biotechnology Research, Medical Testing & Clinical Laboratories, Biotechnology, Immunotherapies, Healthcare, Science and Engineering, Dendritic cells DC, Health Care, T Cell receptors TCR, Pharmaceutical, Rare diseases |
Web Rank | 6 Million |
Keywords | Cancer Treatment, Oncology, Biotechnology, Pharmaceutical, Healthcare |
Competitors | Allogene Therapeutics, Eureka Therapeutics, Inc, Immatics, Immunocore, Tessa Therapeutics Ltd |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Medigene AG employee's phone or email?
The Medigene AG annual revenue was $8 million in 2024.
Selwyn Ho is the CEO of Medigene AG.
83 people are employed at Medigene AG.
Medigene AG is based in Planegg, Bavaria.
The NAICS codes for Medigene AG are [32541, 3254, 325, 32].
The SIC codes for Medigene AG are [28, 283].